StockData
ELI LILLY & Co logo

ELI LILLY & Co

LLYNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 20/3026% above fair value
$1410.99−6.55 (-0.46%)

Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%

Eli Lilly Effient (prasugrel) by Quarter

Effient (prasugrel) — Outside U.S. revenue ($M) [legacy] ($M)

Eli Lilly Effient (prasugrel): $8.80M in Q4 2018, down 32.3% from a year earlier. That is the lowest of the 8 quarters on record here. No newer figure appears in the documents we track.

Latest, Q4 2018
8.80
Period ended Dec 31, 2018
Change on a year earlier
-32.3%
13 in Q4 2017
History
8 quarters
Since Q1 2017
Sources
4
Documents cited below

Where the Q4 2018 figure comes from

Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)

Source: Form 10-K (filed 2019-02-19) ↗

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedEffient (prasugrel) — Outside U.S. revenue ($M) [legacy] ($M)Year on yearSource
Q4 2018Dec 31, 20188.80-32.3%Form 10-K (filed 2019-02-19) ↗
Q3 2018Sep 30, 201815.1+15.3%Form 10-Q (filed 2018-11-06) ↗
Q2 2018Jun 30, 201814.6+22.7%Form 10-Q (filed 2018-07-25) ↗
Q1 2018Mar 31, 201815.7+45.4%Form 10-Q (filed 2018-04-27) ↗
Q4 2017Dec 31, 201713–Form 10-K (filed 2019-02-19) ↗
Q3 2017Sep 30, 201713.1–Form 10-Q (filed 2018-11-06) ↗
Q2 2017Jun 30, 201711.9–Form 10-Q (filed 2018-07-25) ↗
Q1 2017Mar 31, 201710.8–Form 10-Q (filed 2018-04-27) ↗

Cite this data

StockData. (2026). Eli Lilly Effient (prasugrel) ($M), quarterly Q1 2017–Q4 2018 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-effient-nonus

See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.